MoonLake Investors Courted for Lead Role in SDNY Securities Case After SLK Trial Collapse

Overview

• Competing plaintiff firms including Robbins Geller, Rosen, Bernstein Liebhard, DJS Law Group, Frank R. Cruz, Faruqi & Faruqi, and Bleichmar Fonti & Auld are urging MLTX investors to move for lead-plaintiff appointment by December 15, 2025.
• The putative class action, captioned Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612, is pending in the U.S. District Court for the Southern District of New York.
• The proposed class period runs from March 10, 2024 through September 29, 2025 for purchasers or acquirers of MoonLake common stock.
• The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 based on purportedly false statements about sonelokimab’s superiority, including that SLK and BIMZELX target IL-17A and IL-17F and that Nanobody structure would not yield better clinical benefit or efficacy from tissue penetration.
• The suit followed MoonLake’s September 28 disclosure that Phase 3 VELA week‑16 results showed SLK was not competitive with BIMZELX, which preceded an almost 90% one-day share drop, and no class has been certified yet.